江蘇荃信生物醫藥股份有限公司（02509）于2026年2月6日公布翌日披露报表，披露了一项股份购回交易。该公司于2026年2月6日在香港联交所以每股20.06港元至20.38港元的价格区间，回购16,200股H股股份。
本次回购总金额约为325,995.84港元，占该公司回购前已发行股本（不含库存股）约0.0072%。回购完成后，公司已发行股本（不含库存股）变动为224,567,600股，库存股数量增至2,504,000股。该项回购依据2025年6月20日股东大会通过的购回授权进行，授权剩余可回购股份数为22,207,160股。
公司确认本次股份购回符合香港联交所证券上市规则。公告由董事会秘书和联席公司秘书胡衍保签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.